The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards
Meda and Valeant Terminate Joint Ventures
Widening investment-grade credit spreads and rising interest rates lead to losses.
Fund portfolio and Berkshire Hathaway shareholder data show which funds hold significant chunks of the company's stock.
Try this screen for core funds that take the road less travelled.
To say a manager is concentrating bets doesn't tell the whole story.
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.
Valeant Pharmaceuticals VRX announced on Tuesday that its hepatitis C drug candidate Viramidine missed the efficacy endpoint in the second arm of its Phase III clinical trials. We'd previously placed $3 per share of value on this compound's potential, and we plan on reducing our fair value estimate ...
They provide cushions in downturns but don't come for free.